Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $5.07 and traded as low as $4.83. Aldeyra Therapeutics shares last traded at $4.94, with a volume of 362,371 shares.

Aldeyra Therapeutics Trading Down 1.6 %

The business has a fifty day moving average of $5.07 and a two-hundred day moving average of $4.79. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). Equities analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Aldeyra Therapeutics

Institutional investors have recently made changes to their positions in the company. US Bancorp DE acquired a new stake in Aldeyra Therapeutics during the 3rd quarter worth approximately $30,000. Laidlaw Wealth Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 32.6% during the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after buying an additional 4,150 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of Aldeyra Therapeutics in the third quarter valued at about $62,000. The Manufacturers Life Insurance Company grew its stake in shares of Aldeyra Therapeutics by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 2,729 shares in the last quarter. Finally, King Wealth Management Group increased its position in Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 2,700 shares during the period. Institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.